India's Pharmaceutical Industry: Transition from Volume to Value in Global Pharma Market
Contents4
Indian Express - Opinion · 20 Feb 2026 · 2 min read
Prelims · Economy Mains · GS3 Economy High relevance
India's pharmaceutical industry, producing 60% of global medicines, faces the challenge of shifting from volume dominance to capturing higher value share (currently 6%), requiring strategic policy reforms and innovation to achieve $350-billion export target by 2047.
Key points
Global Pharma Leadership: India manufactures 60% of world's medicines, operates over a third of USFDA-approved factories, and supplies 400 billion pills annually to the US market, demonstrating its critical role in global healthcare.
Policy Foundations: The Indian Patents Act 1970 (process patents) and US Hatch-Waxman Act 1984 created legal frameworks enabling generic drug production, reducing prices by up to 90% for critical medications like antiretrovirals.
Economic Impact: India's pharma exports saved global patients $2 trillion in the last decade, with domestic consumption now equaling export volumes, showcasing dual economic and humanitarian impact.
Entrepreneurial Ecosystem: Success stems from policy-entrepreneur synergy, with pioneers like Cipla's Yusuf Hamied and Dr. Reddy's Anji Reddy proving Indian companies can outperform multinationals (only 1 MNC in India's top 10 pharma firms today).
Value Gap Challenge: Despite volume dominance, India captures only 6% of global pharma sales value, highlighting the need for transition to high-value biologics and innovative drugs.
[GS3-Economy] The sector's $350-billion export target by 2047 requires addressing five challenges: research ecosystem, risk capital, ease of business, China competition, and trade barriers.
[GS2-Governance] Policy 2.0 priorities include increased science investment (currently 0.7% of GDP), regulatory simplification, and university-industry collaboration to foster innovation.
Geopolitical Dimension: US-China trade tensions highlight pharma's strategic importance, with India's exemption from US tariffs reflecting its indispensable role in global medicine supply chains.
Way Forward: India should establish a National Pharma Innovation Mission with 10-year tax holidays for R&D, create a $5-billion Biologics Development Fund, and implement single-window clearance for clinical trials to accelerate value-chain transition.
Key terms
- Hatch-Waxman Act
- US law (1984) that established abbreviated approval pathways for generic drugs, including 180-day market exclusivity for first generics. Relevant for UPSC as it demonstrates how regulatory frameworks can stimulate competition and reduce drug prices, with parallels to India's generic drug policies.
- Biologics
- Complex medicines derived from living organisms (unlike chemical-based generics), representing the high-value segment of pharma. For UPSC, biologics signify India's next growth frontier, requiring advanced research infrastructure and regulatory upgrades to compete globally.
- Process Patents
- IP protection for manufacturing methods rather than final products. Crucial for UPSC as India's use of process patents (1970-2005) under TRIPS transition period enabled its generic industry, contrasting with product patents required post-2005 under WTO obligations.
- Indian Patents Act 1970
- Landmark legislation that replaced product patents with process patents for pharmaceuticals, enabling India's generic drug industry. It allowed reverse-engineering of drugs through alternative processes, crucial for affordable medicine production. For UPSC, this represents a case study in strategic policymaking balancing IP rights with public health needs under TRIPS flexibilities.
Practice question
Discuss the challenges and opportunities for India's pharmaceutical industry in transitioning from volume dominance to capturing higher value in the global market. (250 words, 15 marks)
GS3 15 marks 250 words Mains
Key terms to include: Process Patents Indian Patents Act 1970 Hatch-Waxman Act Biologics TRIPS flexibilities Biosimilars USFDA-approved Value-chain transition
Answer framework
Introduction
Briefly introduce India's position as the 'pharmacy of the world' with 60% global medicine production but only 6% value share, highlighting the need for value-chain transition.
Current Strengths and Legacy
India's established generic drug manufacturing ecosystem enabled by Patents Act 1970 and Hatch-Waxman Act
Operational efficiency with 400 billion pills exported annually and 1/3rd USFDA-approved factories
Humanitarian impact: $2 trillion savings for global patients through affordable medicines
Key Challenges in Value Transition
Low R&D investment (0.7% GDP) compared to global peers in innovative drugs/biologics
Competition from China in APIs and complex generics
Regulatory bottlenecks in clinical trials and new drug approvals
Limited risk capital for high-cost biologics development
Strategic Opportunities
Geopolitical advantage: US-China tensions making India preferred pharma partner
Growing domestic market (equal to exports) providing innovation testing ground
Potential in biosimilars and precision medicine as next growth frontiers
Policy Interventions Needed
National Pharma Innovation Mission with tax incentives for R&D
$5-billion Biologics Development Fund for high-risk research
Single-window clearance for clinical trials and regulatory harmonization
Conclusion
Suggest balanced approach - leverage existing volume strengths while systematically building innovation capabilities through public-private partnerships to achieve $350-billion export target by 2047.
Fact check
Issues found Overall severity: medium
India manufactures 60% of world's medicines
The source states India makes 60% of the world's medicines, which matches the claim. Severity: none
operates over a third of USFDA-approved factories
The source mentions India operates more than a third of USFDA-authorised factories, which matches the claim. Severity: none
supplies 400 billion pills annually to the US market
The source states 400 billion of the 800 billion pills consumed by Americans last year were made in India, which matches the claim. Severity: none
The Indian Patents Act 1970 (process patents) and US Hatch-Waxman Act 1984 created legal frameworks enabling generic drug production, reducing prices by up to 90% for critical medications like antiretrovirals.
The source confirms both acts and their impact on generic drug production and price reduction, including the 90% reduction example. Severity: none
India's pharma exports saved global patients $2 trillion in the last decade
The source mentions India saved patients over $2 trillion just in the last decade, which matches the claim. Severity: none
domestic consumption now equaling export volumes
The source states India's domestic consumption of medicines now equals its exports, which matches the claim. Severity: none
only 1 MNC in India's top 10 pharma firms today
The source mentions there is only one MNC in the top 10 by domestic market sales, which matches the claim. Severity: none
India captures only 6% of global pharma sales value
The source states India accounts for only 6% of the world's medicine sales, which matches the claim. Severity: none
$350-billion export target by 2047
The source mentions reaching the $350-billion target in pharma exports by 2047, which matches the claim. Severity: none
increased science investment (currently 0.7% of GDP)
The source does not mention the current science investment as 0.7% of GDP. Severity: medium
India should establish a National Pharma Innovation Mission with 10-year tax holidays for R&D, create a $5-billion Biologics Development Fund, and implement single-window clearance for clinical trials
These specific policy proposals are not mentioned in the source text. Severity: medium